Loss of control of HIV viremia associated with the fat malabsorption drug orlistat

AIDS Res Hum Retroviruses. 2012 Sep;28(9):961-2. doi: 10.1089/AID.2012.0017. Epub 2012 May 3.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenine / administration & dosage
  • Adenine / adverse effects
  • Adenine / analogs & derivatives*
  • Adult
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / adverse effects*
  • Anti-Obesity Agents / adverse effects*
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / adverse effects
  • Deoxycytidine / analogs & derivatives*
  • Drug Combinations
  • Drug Interactions
  • Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
  • HIV / drug effects*
  • HIV / genetics
  • HIV / isolation & purification
  • HIV Seropositivity / blood
  • HIV Seropositivity / drug therapy*
  • Humans
  • Lactones / adverse effects*
  • Male
  • Nonprescription Drugs / adverse effects*
  • Obesity / chemically induced*
  • Organophosphonates / administration & dosage
  • Organophosphonates / adverse effects*
  • Orlistat
  • Oxazines / administration & dosage
  • Oxazines / adverse effects*
  • RNA, Viral / blood
  • RNA, Viral / drug effects
  • Reverse Transcriptase Inhibitors / administration & dosage
  • Reverse Transcriptase Inhibitors / adverse effects*
  • Viral Load / drug effects*

Substances

  • Anti-HIV Agents
  • Anti-Obesity Agents
  • Drug Combinations
  • Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
  • Lactones
  • Nonprescription Drugs
  • Organophosphonates
  • Oxazines
  • RNA, Viral
  • Reverse Transcriptase Inhibitors
  • Deoxycytidine
  • Orlistat
  • Adenine